The Biosafety Level-3 (BL-3) Core Facility is designed to provide an efficient, cost-effective, and safe environment for CFAR and other investigators involved in AIDS and AIDS-related research such that both ongoing projects will benefit and new collaborations will be fostered. Since culture of biohazardous pathogens including HIV, SIV, HTLV-I and virulent M. tuberculosis is an absolute requirement for many CFAR investigators, this facility is essential. The new BL-3 Facility (1127 sq ft) is scheduled for completion in October 1993, and is located on the 10th floor of the Biomedical Research Building, in the Division of Infectious Disease. The Facility has recently been equipped to the greater extent by the CWRU School of Medicine. Equipment includes 5 laminar flow hoods, centrifuges, incubators, -70C freezers, microscopes, thermal cycler and ELISA reader. The Facility is comprised of 6 rooms, the 3 largest for biohazardous activities. One room will be devoted to research involving virulent M. tuberculosis and another to HIV, SIV, and HTLV-I. Other rooms house common equipment. The BL-3 Core Facility will be administered by a BL-3 Advisory Group comprised of members of the CFAR; Dr. Rich (Director of the BL-3 Core Facility), Dr. LeGrice, and De. Lederman. Dr. Rich's laboratory is adjacent to the BL-3 Facility. Projects performed in the BL-3 Facility will be established beginning in funding year 02 to cover costs of the Facility such that by year 05, 70% of these will be generated by such fees. Multidisciplinary collaboration will be fostered by the BL-3 Core Facility by three main mechanisms: 1) Through interactions among users of the facility; 2) Through services rendered by a full-time research assistant in the facility including viral stock preparation, HIV infections of cells, p24 ELISAs, and teaching of these techniques to new investigators. 3) Quarterly meetings by all users and interested faculty discussing results obtained from experiments performed in the facility.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI036219-03
Application #
5205753
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
1996
Total Cost
Indirect Cost
Kityo, Cissy; Makamdop, Krystelle Nganou; Rothenberger, Meghan et al. (2018) Lymphoid tissue fibrosis is associated with impaired vaccine responses. J Clin Invest 128:2763-2773
Wiredja, Danica D; Tabler, Caroline O; Schlatzer, Daniela M et al. (2018) Global phosphoproteomics of CCR5-tropic HIV-1 signaling reveals reprogramming of cellular protein production pathways and identifies p70-S6K1 and MK2 as HIV-responsive kinases required for optimal infection of CD4+ T cells. Retrovirology 15:44
Oliveira, Vitor H F; Perazzo, Joseph D; Josephson, Richard A et al. (2018) Association Between the 6-Minute Walk Test Distance and Peak Cardiorespiratory Fitness Among People Living with HIV Varies by Fitness Level. J Assoc Nurses AIDS Care 29:775-781
Paparisto, Ermela; Woods, Matthew W; Coleman, Macon D et al. (2018) Evolution-Guided Structural and Functional Analyses of the HERC Family Reveal an Ancient Marine Origin and Determinants of Antiviral Activity. J Virol 92:
Llewellyn, George N; Alvarez-Carbonell, David; Chateau, Morgan et al. (2018) HIV-1 infection of microglial cells in a reconstituted humanized mouse model and identification of compounds that selectively reverse HIV latency. J Neurovirol 24:192-203
Longenecker, Chris T; Sullivan, Claire E; Morrison, Justin et al. (2018) The effects of HIV and smoking on aortic and splenic inflammation. AIDS 32:89-94
Tomas, Myreen E; Mana, Thriveen S C; Wilson, Brigid M et al. (2018) Tapering Courses of Oral Vancomycin Induce Persistent Disruption of the Microbiota That Provide Colonization Resistance to Clostridium difficile and Vancomycin-Resistant Enterococci in Mice. Antimicrob Agents Chemother 62:
Yanik, Elizabeth L; Hernández-Ramírez, Raúl U; Qin, Li et al. (2018) Brief Report: Cutaneous Melanoma Risk Among People With HIV in the United States and Canada. J Acquir Immune Defic Syndr 78:499-504
Sahmoudi, Karima; Abbassi, Hassan; Bouklata, Nada et al. (2018) Immune activation and regulatory T cells in Mycobacterium tuberculosis infected lymph nodes. BMC Immunol 19:33
Webel, Allison R; Moore, Shirley M; Longenecker, Chris T et al. (2018) Randomized Controlled Trial of the SystemCHANGE Intervention on Behaviors Related to Cardiovascular Risk in HIV+ Adults. J Acquir Immune Defic Syndr 78:23-33

Showing the most recent 10 out of 539 publications